The European Commission approved the project Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials, PRIME-ROSE on 24 April 2023. The project will run for five years (2023-2028) and is funded by the European Commission Horizon Europe Mission on Cancer with 6 mill EUR. The consortium consists of altogether 24 partners, including nine beneficiaries and fifteen associated partners.
The pan-European PRIME-ROSE project is led by Professor Kjetil Taskén, Head of Institute for Cancer Research at Oslo University Hospital. OUH will receive about 20 mill NOK.
Press release (PDF)
News article from the homepage of Matrix:
PRIME-ROSE: EU-project receives 6 million EUR from EU Cancer Mission - Matrix (matrix-fkb.no)
From the Oslo University Hospital homepage:
Millionstøtte til OUS-ledet EU-prosjekt innen persontilpasset kreftbehandling (oslo-universitetssykehus.no)